Please login to the form below

Not currently logged in
Email:
Password:

UCB extends agreement with Novartis

UCB Germany has made an agreement with Novartis to extend commercial rights in Germany for the cardiovascular medication Provas beyond 2011

UCB Germany, an affiliate of the Belgian biopharmaceutical company, has made an agreement with Novartis to extend commercial rights in Germany for the cardiovascular medication Provas (valsartan) beyond 2011. 

The company has also negotiated rights for the hypertension treatments Dafiro (valsartan and amlodipine) and Dafiro HCT (valsartan, amlodipine and HCT) and will also co-market  two new oral diabeties therapies Jalra (vildagliptin Icandra and vildagliptin + metformin).

Willy Cnops, vice president  of UCB and managing director of the German operation, said in a  statement: "We are extending our cardiovascular and metabolic product portfolio with the most attractive and innovative treatment options to date in line with UCB's ambitions to offer the best medicines to our patients."

25th August 2009

Share

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
An agency called Owen

We’re a Healthcare Communications Agency specialising in Multi-channel Marketing to make you Digitally Fitter, Stronger & Faster....

Latest intelligence

patients
Retaining reader value in plain language summaries of clinical studies
Balancing the risk of misinterpretation with the public’s ability to understand simplified plain-language summaries...
Can we talk about the ego-bias and chemicals influencing your target audience’s behaviour?
Over the Summer, the Page & Page team became fascinated by two books on this very subject. Two books from one author, Dean Burnett, an eminent neuroscientist, lecturing at Cardiff...
Paris
Making Europe a leader in bioscience: boosting trust and opening minds
A vision of Paris as Europe's leading hub for life sciences innovation...

Infographics